IL23A and psoriasis: The fact that IL-12, but not IL-23, is the pathogenetically relevant pathway in AD-related IL-12/IL-23 signaling—of note and in contrast to other IL-12/IL-23-mediated (non-neurological) disorders, such as Crohn’s disease, rheumatoid arthritis or psoriasis, where IL-23 is the main player—may also encourage the use of exclusive IL-12 inhibition in tackling AD.